Kular, Lara
Liu, Yun
Ruhrmann, Sabrina
Zheleznyakova, Galina
Marabita, Francesco http://orcid.org/0000-0001-6180-0106
Gomez-Cabrero, David
James, Tojo
Ewing, Ewoud http://orcid.org/0000-0001-8644-366X
Lindén, Magdalena
Górnikiewicz, Bartosz
Aeinehband, Shahin
Stridh, Pernilla
Link, Jenny http://orcid.org/0000-0002-6134-9404
Andlauer, Till F. M. http://orcid.org/0000-0002-2917-5889
Gasperi, Christiane
Wiendl, Heinz
Zipp, Frauke http://orcid.org/0000-0002-1231-1928
Gold, Ralf
Tackenberg, Björn
Weber, Frank
Hemmer, Bernhard
Strauch, Konstantin
Heilmann-Heimbach, Stefanie
Rawal, Rajesh
Schminke, Ulf
Schmidt, Carsten O.
Kacprowski, Tim http://orcid.org/0000-0002-5393-2413
Franke, Andre http://orcid.org/0000-0003-1530-5811
Laudes, Matthias
Dilthey, Alexander T.
Celius, Elisabeth G.
Søndergaard, Helle B.
Tegnér, Jesper
Harbo, Hanne F.
Oturai, Annette B.
Olafsson, Sigurgeir
Eggertsson, Hannes P. http://orcid.org/0000-0002-1674-9978
Halldorsson, Bjarni V. http://orcid.org/0000-0003-0756-0767
Hjaltason, Haukur
Olafsson, Elias
Jonsdottir, Ingileif
Stefansson, Kari
Olsson, Tomas
Piehl, Fredrik
Ekström, Tomas J.
Kockum, Ingrid
Feinberg, Andrew P. http://orcid.org/0000-0002-8364-1991
Jagodic, Maja
Article History
Received: 9 January 2018
Accepted: 17 May 2018
First Online: 19 June 2018
Competing interests
: Sigurgeir Olafsson, Hannes P. Eggertsson, Bjarni V. Halldorsson, Ingileif Jonsdottir and Kari Stefanssonare employees of deCODE genetics/Amgen Inc at the time work related to this study was carried out.H.F. Harbo has received honoraria for advice and lecturing from Biogen, Genzyme, Merck, Novartis,Sanofi-Aventis and Teva. She has received modest unrestricted research grant for research fromNovartis. B. Tackenberg received personal speaker honoraria and consultancy fees as a speaker andadvisor from Bayer Healthcare, Biogen, CSL Behring, GRIFOLS, Merck Serono, Novartis, Octapharma,Roche, Sanofi Genzyme, TEVA und UCB Pharma. His University received unrestricted research grantsfrom Biogen-idec, Novartis, TEVA, Bayer Healthcare, CSL-Behring, GRIFOLS, Octapharma, SanofiGenzyme and UCB Pharma. B. Hemmer has served on scientific advisory boards for F. Hoffmann-LaRoche Ltd, Novartis, Bayer AG, and Genentech; he has served as DMSC member for AllergyCare and TGtherapeutics; he or his institution have received speaker honoraria from Biogen Idec, TevaNeuroscience, Merck Serono, Medimmune, Novartis, Desitin, and F. Hoffmann-La Roche Ltd; hisinstitution has received research support from Chugai Pharmaceuticals and Biogen; holds part of two patents; one for the detection of antibodies against KIR4.1 in a subpopulation of MS patients and one for genetic determinants of neutralizing antibodies to interferon β. The remaining authors declare no competing interests.